Paid Clinical Trials in Connecticut
Connecticut has 1,295 paid clinical trials enrolling now across cities including New Haven, Hartford and Stamford. Search by condition, age, or phase to find compensated research studies accepting participants near you.
Research sites in Connecticut include Yale University, National Cancer Institute (NCI) and Eli Lilly and Company, running studies across oncology, cardiology, neurology, and more. The most actively recruiting conditions are Breast Cancer, Advanced Solid Tumor, Alcohol Use Disorder, Heart Failure — browse the full list or use the filters to match your diagnosis. Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Connecticut
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 2
A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20
A Study of the Pharmacokinetics, Biodistribution and Dosimetry of Granzyme-B Targeted [Cu-64]-Labeled PET Radiotracers in Adult Healthy Volunteers
Real-time Opioid Study
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
1,144 clinical trials
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
A Study of Brenipatide in Adult Participants With Schizophrenia
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Study of DONQ52 in Active Celiac Disease
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
A Study of Buntanetap in Participants With PD
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Common conditions studied in Connecticut
- Breast Cancer (25 active studies)
- Advanced Solid Tumor (22 active studies)
- Alcohol Use Disorder (19 active studies)
- Heart Failure (17 active studies)
- Advanced Solid Tumors (16 active studies)
- Obesity (16 active studies)
Leading research sponsors in Connecticut
- Yale University
- National Cancer Institute (NCI)
- Eli Lilly and Company
- AstraZeneca
- VA Office of Research and Development
Frequently asked questions
How many paid clinical trials are currently recruiting in Connecticut?
There are approximately 1,295 recruiting clinical trials in Connecticut listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Connecticut pay participants?
Most recruiting trials in Connecticut compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Connecticut?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Connecticut?
The most common conditions under active study in Connecticut include Breast Cancer (25), Advanced Solid Tumor (22), Alcohol Use Disorder (19), Heart Failure (17), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Connecticut?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Connecticut on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Connecticut?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.